NASDAQ:SURF - Surface Oncology Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $10.10 +0.33 (+3.38 %) (As of 08/19/2018 11:23 AM ET)Previous Close$10.10Today's Range$9.70 - $10.351452-Week Range$9.02 - $18.18Volume222,759 shsAverage Volume244,938 shsMarket Capitalization$286.74 millionP/E RatioN/ADividend YieldN/ABetaN/A Company ProfileAnalyst RatingsChartEarnings HistoryInsider TradesHeadlinesOptions ChainSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company's lead product candidate is the SRF231 that is in Phase I clinical trial targeting protein called cluster of differentiation (CD) 47. It is also developing SRF373 inhibiting CD73; SRF617 inhibiting CD39; and SRF388, an antibody targeting interleukin 27. The company has a collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts. Receive SURF News and Ratings via Email Sign-up to receive the latest news and ratings for SURF and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical SymbolNASDAQ:SURF CUSIPN/A Webwww.surfaceoncology.com Phone617-714-4096 Debt Debt-to-Equity RatioN/A Current Ratio4.19 Quick Ratio4.19 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$45.49 million Price / Sales6.13 Cash Flow$1.1136 per share Price / Cash9.07 Book Value($0.76) per share Price / Book-13.29 Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees56 Outstanding Shares27,610,000Market Cap$286.74 million Surface Oncology (NASDAQ:SURF) Frequently Asked Questions What is Surface Oncology's stock symbol? Surface Oncology trades on the NASDAQ under the ticker symbol "SURF." How were Surface Oncology's earnings last quarter? Surface Oncology Inc (NASDAQ:SURF) announced its earnings results on Tuesday, August, 14th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.76) by $0.03. The business had revenue of $2.43 million for the quarter. View Surface Oncology's Earnings History. When is Surface Oncology's next earnings date? Surface Oncology is scheduled to release their next quarterly earnings announcement on Tuesday, November, 13th 2018. View Earnings Estimates for Surface Oncology. What price target have analysts set for SURF? 3 Wall Street analysts have issued 12 month price objectives for Surface Oncology's shares. Their predictions range from $17.00 to $26.00. On average, they expect Surface Oncology's stock price to reach $21.50 in the next year. This suggests a possible upside of 112.9% from the stock's current price. View Analyst Price Targets for Surface Oncology. What is the consensus analysts' recommendation for Surface Oncology? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surface Oncology in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Surface Oncology. Who are some of Surface Oncology's key competitors? Some companies that are related to Surface Oncology include DBV TECHNOLOGIE/S (DBVT), Autolus Therapeutics (AUTL), Avrobio (AVRO), BAVARIAN NORDIC/S (BVNRY), Adaptimmune Therapeutics (ADAP), BioCryst Pharmaceuticals (BCRX), Heska (HSKA), CASI Pharmaceuticals (CASI), Fate Therapeutics (FATE), La Jolla Pharmaceutical (LJPC), Mesoblast (MESO), Voyager Therapeutics (VYGR), Vericel (VCEL), Novavax (NVAX) and Replimune Group (REPL). Who are Surface Oncology's key executives? Surface Oncology's management team includes the folowing people: Mr. Daniel S. Lynch, Exec. Chairman (Age 60)Mr. J. Jeffrey Goater, CEO, Pres, Sec. & Director (Age 43)Dr. Vito J. Palombella, Chief Scientific Officer (Age 55)Dr. Scott C. Chappel, Chief Technology Officer (Age 67)Dr. Robert W. Ross, Chief Medical Officer (Age 44) When did Surface Oncology IPO? (SURF) raised $84 million in an initial public offering (IPO) on Thursday, April 19th 2018. The company issued 6,000,000 shares at a price of $13.00-$15.00 per share. Goldman Sachs, Cowen and Evercore ISI served as the underwriters for the IPO. When does Surface Oncology's lock-up period expire? Surface Oncology's lock-up period expires on Tuesday, October 16th. Surface Oncology had issued 7,200,000 shares in its IPO on April 19th. The total size of the offering was $108,000,000 based on an initial share price of $15.00. After the end of Surface Oncology's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted. Has Surface Oncology been receiving favorable news coverage? Headlines about SURF stock have been trending somewhat positive this week, Accern reports. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Surface Oncology earned a media and rumor sentiment score of 0.17 on Accern's scale. They also gave press coverage about the company an impact score of 48.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future. View Recent Headlines for Surface Oncology. Who are Surface Oncology's major shareholders? Surface Oncology's stock is owned by a number of of retail and institutional investors. Top institutional investors include Atlas Venture Associates IX LLC (16.83%), NEA Management Company LLC (12.01%), FMR LLC (10.66%), Citadel Advisors LLC (3.14%), BlackRock Inc. (2.27%) and Victory Capital Management Inc. (2.06%). Company insiders that own Surface Oncology stock include David S Grayzel and Lilly Ventures Fund I Llc. View Institutional Ownership Trends for Surface Oncology. Which major investors are buying Surface Oncology stock? SURF stock was bought by a variety of institutional investors in the last quarter, including Atlas Venture Associates IX LLC, NEA Management Company LLC, FMR LLC, Citadel Advisors LLC, BlackRock Inc., Victory Capital Management Inc., Millennium Management LLC and Bank of America Corp DE. Company insiders that have bought Surface Oncology stock in the last two years include David S Grayzel and Lilly Ventures Fund I Llc. View Insider Buying and Selling for Surface Oncology. How do I buy shares of Surface Oncology? Shares of SURF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Surface Oncology's stock price today? One share of SURF stock can currently be purchased for approximately $10.10. How big of a company is Surface Oncology? Surface Oncology has a market capitalization of $286.74 million and generates $45.49 million in revenue each year. Surface Oncology employs 56 workers across the globe. How can I contact Surface Oncology? Surface Oncology's mailing address is 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-714-4096 or via email at [email protected] MarketBeat Community Rating for Surface Oncology (NASDAQ SURF)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 28 (Vote Outperform)Underperform Votes: 23 (Vote Underperform)Total Votes: 51MarketBeat's community ratings are surveys of what our community members think about Surface Oncology and other stocks. Vote "Outperform" if you believe SURF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SURF will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/19/2018 by MarketBeat.com StaffFeatured Article: What is the Book Value of a Share?